PEN Penumbra Inc
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1321732 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.0%
TTM net income YoY-4.3%
TTM EPS YoY-5.3%
Revenue 3-yr CAGR16.2%
Net income 3-yr CAGR56.9%
Margins
Gross margin68.0%
Operating margin12.1%
Net margin10.1%
FCF margin12.8%
EBITDA margin13.4%
Returns
ROE10.7%
ROA8.3%
ROIC (approx.)12.1%
Asset turnover0.83x
Leverage & solvency
Liabilities / assets21.8%
Debt / equity0.00x
Current ratio5.89x
Interest coverage149.48x
Cash quality & payout
Operating cash flow / net income1.66x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue3.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.40B | $1.19B |
| Cost of revenue | $461.23M | $439.62M |
| Gross profit | $942.44M | $755.00M |
| R&D expense | $89.77M | $94.78M |
| SG&A expense | $663.42M | $573.99M |
| Operating income | $189.25M | $9.28M |
| Interest expense | $1.31M | $1.42M |
| Pretax income | $205.12M | $20.87M |
| Income tax | $27.44M | $6.86M |
| Net income | $177.69M | $14.01M |
| EBITDA | $206.72M | $32.98M |
| EPS (basic) | 4.57 | 0.36 |
| EPS (diluted) | 4.52 | 0.36 |
| Weighted avg. shares (diluted) | 39.29M | 39.27M |
| Balance sheet | ||
| Cash & equivalents | $186.90M | $324.40M |
| Short-term investments | $357.92M | $15.73M |
| Receivables | $190.02M | $167.67M |
| Inventory | $431.55M | $406.74M |
| Current assets | $1.22B | $951.12M |
| PP&E, net | $117.44M | $62.64M |
| Goodwill | $166.75M | $165.83M |
| Intangibles | $6.19M | $6.51M |
| Total assets | $1.83B | $1.53B |
| Current liabilities | $183.13M | $158.34M |
| Total liabilities | $398.92M | $382.25M |
| Shareholders' equity | $1.43B | $1.15B |
| Shares outstanding | 39.23M | 38.49M |
| Cash flow statement | ||
| Operating cash flow | $238.66M | $168.48M |
| Capital expenditure | $63.73M | $21.18M |
| Free cash flow | $174.93M | $147.30M |
| Investing cash flow | -$404.59M | $77.62M |
| Financing cash flow | $26.53M | -$87.01M |
| Depreciation & amortization | $17.47M | $23.70M |
| Stock-based compensation | $59.21M | $46.16M |
| Share buybacks | $0 | $100.39M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.